-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) combined with endocrine therapy has now become the standard regimen for first-line treatment of hormone receptor-positive metastatic breast cancer (HR+MBC) or after the advancement of endocrine therapy.
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) combined with endocrine therapy has now become the standard regimen for first-line treatment of hormone receptor-positive metastatic breast cancer (HR+MBC) or after the advancement of endocrine therapy.
Therefore, foreign scholars have published related studies in the Journal of The National Comprehensive Cancer Network (JNCCN), focusing on the efficacy of the C DK4/6 inhibitor piperacillil after the progress of the treatment with abecili .
The multi-center retrospective study, mainly under US- Guo 6 Cancer Center in 87 cases + HR MBC patients, use first-line treatment for all patients are piperazine Bo Xili .
The multi-center retrospective study, mainly into the United States six cancer centers country of 87 cases of HR + MBC The multi-center retrospective study, mainly into the United States six cancer centers country of 87 cases of HR + MBC patients, first-line treatment for all patients All applied is pibacillil .
The research data showed that among the 87 patients enrolled, the median progression-free survival (PFS) of the patients treated with abexilide was 5.
After the failure of the patient’s CDK4/6 inhibitor pebacillil treatment, 80.
Subsequent studies showed that the duration of pipercillide-based treatment was not significantly correlated with the duration of subsequent abecilide treatment.
The patients who received abexilide were well tolerated, and only a few patients (9.
Treatment- related adverse events
Researchers have also tried to use next-generation sequencing (NGS) to find predictive markers of drug resistance, and studies have shown that it may be related to changes in RB1, ERBB2, and CCNE1 related factors.
To sum up, the use of abecilil for treatment of breast cancer patients with the CDK4/6 inhibitor pepicilide still has clinical benefit after progression.
To sum up, the use of abecilil for treatment of breast cancer patients with the CDK4/6 inhibitor pepicilide still has clinical benefit after progression.
There is still clinical benefit in the treatment of breast cancer patients with the CDK4/6 inhibitor pebrocillil after progression.
Original source:
Original source:A.
Wander seth,Hyo S.
Han, Mark L.
Zangardi,.
Et Al Clinical Outcomes, Prior, the After With Abemaciclib of CDK4 / Progression.
6 Inhibitor in Breast Cancer: A Multicenter Experienc E .
Journal of The National, Comprehensive Cancer of the Network .
2021 .
The DOI:org/10.
6004/jnccn.
2020.
7662">https://doi.
org/10.
6004/jnccn.
2020.
7662
Wander seth, Hyo S.
Han, Mark L.
Zangardi, .
Et Al Clinical Outcomes, Prior, the After With Abemaciclib of CDK4 / Progression.
6 Inhibitor in Breast Cancer: A Multicenter Experienc E .
Journal of The National, Comprehensive Cancer of the Network .
2021 .
The DOI: org/10.
6004/jnccn.
2020.
7662">https://doi.
org/10.
6004/jnccn.
2020.
7662 Seth A.
Wander, Hyo S.
Han, Mark L.
Zangardi, et al.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experienc e .
Journal of The National, Comprehensive Cancer of the Network .
2021 .
the DOI: org/10.
6004/jnccn.
2020.
7662">https://doi.
org/10.
6004/jnccn.
2020.
7662 https://doi.
org/10.
6004/jnccn.
2020.
7662
Leave a message here
